Cost-Benefit Analysis

"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.

Descriptor ID	D003362
MeSH Number(s)	N03.219.151.125
Concept/Terms	Cost-Benefit Analysis Cost-Benefit Analysis Analyses, Cost-Benefit Analysis, Cost-Benefit Cost-Benefit Analyses Cost Benefit Analysis Analyses, Cost Benefit Analysis, Cost Benefit Cost Benefit Analyses Cost Effectiveness Cost Effectiveness Effectiveness, Cost Cost-Benefit Data Cost-Benefit Data Cost Benefit Data Data, Cost-Benefit Cost-Utility Analysis Cost-Utility Analysis Analyses, Cost-Utility Analysis, Cost-Utility Cost Utility Analysis Cost-Utility Analyses Economic Evaluation Economic Evaluation Economic Evaluations Evaluation, Economic Evaluations, Economic Marginal Analysis Marginal Analysis Analyses, Marginal Analysis, Marginal Marginal Analyses Cost Benefit Cost Benefit Costs and Benefits Benefits and Costs Cost-Effectiveness Analysis Cost-Effectiveness Analysis Analysis, Cost-Effectiveness Cost Effectiveness Analysis

Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".

Health Care [N]
Health Care Economics and Organizations [N03]
Economics [N03.219]
Costs and Cost Analysis [N03.219.151]
Cost-Benefit Analysis [N03.219.151.125]

Below are MeSH descriptors whose meaning is related to "Cost-Benefit Analysis".

Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.

Bar chart showing 181 publications over 27 distinct years, with a maximum of 15 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	1	1
1994	0	1	1
1997	0	1	1
1998	0	3	3
2000	0	3	3
2002	0	3	3
2003	0	7	7
2004	1	4	5
2005	1	6	7
2006	2	5	7
2007	0	5	5
2008	0	6	6
2009	0	8	8
2010	0	9	9
2011	0	5	5
2012	0	5	5
2013	0	7	7
2014	2	13	15
2015	1	12	13
2016	6	8	14
2017	5	9	14
2018	1	5	6
2019	1	4	5
2020	0	14	14
2021	3	6	9
2022	0	5	5
2023	0	3	3

Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.

Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 Sep 05; 6(9):e2329583.

View in: PubMed
Wang L, Lauren BN, Hager K, Zhang FF, Wong JB, Kim DD, Mozaffarian D. Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study. J Am Heart Assoc. 2023 08; 12(15):e029215.

View in: PubMed
Jia X, Wang R, Hall C, Flynn MK. Cost-effectiveness Analysis: Autologous Rectus Fascial Sling Versus Retropubic Midurethral Sling for Female Stress Urinary Incontinence. Urogynecology (Phila). 2023 02 01; 29(2):104-112.

View in: PubMed
Boteon YL, Boteon APCS, Martins PN. Comment on: Cost-utility analysis of normothermic and hypothermic ex-situ machine perfusion in liver transplantation. Br J Surg. 2022 10 14; 109(11):e123.

View in: PubMed
Resch SC, Suarez S, Omotayo MO, Griffin J, Sessler D, Burke T. Non-anaesthetist-administered ketamine for emergency caesarean section in Kenya: cost-effectiveness analysis. BMJ Open. 2022 10 05; 12(10):e051055.

View in: PubMed
Chen W, Khurshid S, Singer DE, Atlas SJ, Ashburner JM, Ellinor PT, McManus DD, Lubitz SA, Chhatwal J. Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices. JAMA Health Forum. 2022 08; 3(8):e222419.

View in: PubMed
Coderre D, Brahmbhatt P, Hunter TL, Baima J. Cancer Prehabilitation in Practice: the Current Evidence. Curr Oncol Rep. 2022 Nov; 24(11):1569-1577.

View in: PubMed
Gabot A, Lavitas P, Bacon R, Pomfret TC, Taylor M, Coelho A, Greenwood BC, Alper CJ, Clements KM, Lenz K. Cost-benefit analysis of sacubitril/valsartan in a Medicaid population. Am J Manag Care. 2022 07; 28(7):349-352.

View in: PubMed
Burchard J, Markenson GR, Saade GR, Laurent LC, Heyborne KD, Coonrod DV, Schoen CN, Baxter JK, Haas DM, Longo SA, Sullivan SA, Wheeler SM, Pereira LM, Boggess KA, Hawk AF, Crockett AH, Treacy R, Fox AC, Polpitiya AD, Fleischer TC, Garite TJ, Jay Boniface J, Zupancic JAF, Critchfield GC, Kearney PE. Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a large and diverse cohort. J Med Econ. 2022 Jan-Dec; 25(1):1255-1266.

View in: PubMed
Boteon YL, Hessheimer AJ, Br?ggenwirth IMA, Boteon APCS, Padilla M, de Meijer VE, Dom?nguez-Gil B, Porte RJ, Perera MTPR, Martins PN. The economic impact of machine perfusion technology in liver transplantation. Artif Organs. 2022 Feb; 46(2):191-200.

View in: PubMed

People

Explore

Similar Concepts

Top Journals